IPOs: Enanta Wows While Tetraphase Gets The Job Done
This article was originally published in The Pink Sheet Daily
A pair of biotech IPOs priced on March 20 with mixed results. Hepatitis C developer Enanta got a warm reception from investors looking to tap into what has been a lucrative sector. But antibiotics company Tetraphase priced below its range and traded flat.